Will HeartSciences stock go up?

According to Danelfin AI, HeartSciences has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (40.18%) is -10.64% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for HeartSciences stock?

The HeartSciences target price is $9.93 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold HeartSciences stock right now?

HeartSciences has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (40.18%) is -10.64% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether HeartSciences stock is a good buy .

Is HeartSciences undervalued right now?

Based on analysts, the average price target upside for HeartSciences is +240.14% (1Y). According to Danelfin AI, HeartSciences has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of HeartSciences stock over the past 12 months?

The HeartSciences stock price range over the past 12 months has been $1.67 - $5.73.

What is going on with HeartSciences stock in the last 3 months?

The HeartSciences stock performance in the last quarter has been +16.14%.

Does HeartSciences offer dividend payments?

No, HeartSciences does not currently pay dividends.

What is the current market capitalization of HeartSciences?

HeartSciences's market cap is $9.68M, as of 2026-07-02 08:00.

When is the next HSCS earnings report date?

HSCS will publish its next earnings report on 2026-03-12.

HeartSciences Inc (HSCS) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

HSCS AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Growth+0.59%
Expected pace of revenue and earnings expansion

Valuation-3.01%
How the stock is priced relative to its fundamentals
Momentum-2.90%
Direction and strength of recent price movements
Sentiment-2.63%
How analysts and the market view the stock
Profitability-0.91%
Profitability and operating efficiency metrics
Size & Liquidity-0.88%
Company size and trading liquidity
Earnings Quality-0.48%
Stability and reliability of reported earnings
Volatility-0.42%
How much the stock price tends to fluctuate

HSCS probability advantage of beating the market (3M):

-10.64%

AI Score

Strong Sell

HeartSciences (HSCS) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -10.64% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of HSCS (40.18%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
HSCS probability advantage of beating the market (3M)-10.64%
HSCS probability of beating the market (3M)40.18%

HSCS probability advantage of beating the market (3M): -10.64%

The AI-powered overall analysis of HeartSciences (HSCS) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of HSCS:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-2.03%
Technical	Chart Pattern (504d)	figure_23	N/A	-1.84%
Technical	Technicals Impact (Long Tail)	-	N/A	-1.15%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.15%
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-1.11%
Technical	Maximum Volatility	23.35%		-0.93%
Fundamental	Beginning Cash (Millions)	1.1	N/A	-0.88%
Technical	Chart Pattern (180d)	figure_104	N/A	-0.80%
Technical	Chart Pattern (90d)	figure_19	N/A	+0.71%
Technical	Chart Pattern (252d)	figure_85	N/A	+0.66%
Sentiment	Upgrade to unlock			+0.62%
Sentiment	Upgrade to unlock			-0.60%
Sentiment	Upgrade to unlock			+0.59%
Technical	Upgrade to unlock			+0.58%
Technical	Upgrade to unlock			-0.55%

Rest of Alpha Signals: -2.76%

HSCS probability advantage of beating the market (3M)Total:-10.64%
HSCS AI Score

Significant changes Vs previous day

HSCS Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$2.92
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

HSCS Proven Sell Signal & Price Forecast

This is the price chart for HSCS from January 1, 2026 until today. The chart indicates, in red, the 84 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

HSCS Average Past Performance & Loss Rate

Three months after its 889 Sell signals since July 2026, HSCS had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

889 Past HSCS Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-60.79%
Average Alpha				-80.07%
Loss Rate (% Negative Perf.)				92.04%
% Negative Alpha				98.13%

HSCS Frequently Asked Questions

Will HeartSciences stock go up?
According to Danelfin AI, HeartSciences has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (40.18%) is -10.64% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for HeartSciences stock?
Is it a good time to buy, sell, or hold HeartSciences stock right now?
Is HeartSciences undervalued right now?
What was the price range of HeartSciences stock over the past 12 months?
What is going on with HeartSciences stock in the last 3 months?
Does HeartSciences offer dividend payments?
What is the current market capitalization of HeartSciences?
When is the next HSCS earnings report date?

HeartSciences Inc Company Profile

With a focus on medical technology, Heart Test Laboratories, Inc., plays an integral role in the field of cardiovascular diagnostics. It has shaped its reputation around the production of distinguished offerings like the MyoVista wavECG - an advanced device that puts to use resting 12-lead electrocardiograph (ECG) technology. This innovative tool not only provides traditional ECG data but also offers crucial diagnostic insight into cardiac dysfunction.

Operating as a key resource for healthcare professionals, Heart Test Laboratories caters to a variety of environments where wellness takes priority. Its client roster expands from multiple clinics and doctor’s offices to urgent care centers and hospitals; they all trustfully employ the company's state-of-the-art solutions for reliable patient examinations.

Incorporated in the year 2007, Heart Test Laboratories continues its operations from Southlake, Texas - serving as its established headquarters. As it engages in enriching lives with safer and accurate diagnoses, it balances sophistication with ease-of-use in its technological exploits while catering to the ever-evolving medical landscape.

Sector:
Country:United States
Industry:
Address:550 Reserve St, Suite 360, Southlake
Employees:15
Website:heartsciences.com

Pros

Proprietary AI-driven ECG diagnostic technology

High switching costs for integrated diagnostic systems

Scalability of software-based medical diagnostics

Regulatory barriers to entry for novel devices

Potential for improved diagnostic accuracy in cardiology

Cons

Extensive regulatory approval processes for medical devices

HSCS Stock AI Analysis